New hope for Hard-to-Treat breast cancer: SKB264 takes on chemo in major trial
NCT ID NCT06279364
First seen Jan 30, 2026 · Last updated Apr 30, 2026 · Updated 17 times
Summary
This study tests a new drug called SKB264 as the first treatment for people with advanced triple-negative breast cancer that cannot be removed by surgery or has spread. About 524 participants will receive either SKB264 or standard chemotherapy. The goal is to see if SKB264 helps people live longer and slows cancer growth better than current options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.